Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 4,356 shares at $25.00 ($109K) on 2026-08-05, disclosed to the SEC on 2026-08-05.
Scheduled sale ($109k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NRIX | SELL | 2026-07-30 | $90K | — | Filing → |
| NRIX | SELL | 2026-06-25 | $108K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $53K | — | Filing → |